Literature DB >> 16251386

Further evidence that ribavirin interacts with eIF4E.

Alex Kentsis1, Laurent Volpon, Ivan Topisirovic, Clifford E Soll, Biljana Culjkovic, Ling Shao, Katherine L B Borden.   

Abstract

This commentary discusses the recent reports in RNA by Yan and colleagues and Westman and colleagues of the apparent failure of ribavirin to bind to recombinant eIF4E and inhibit 7-methyl guanosine cap-dependent exogenous mRNA translation of cell extracts in vitro. Measuring binding by using affinity chromatography of matrix-immobilized proteins and by using protein emission fluorescence spectroscopy in the presence of nucleotide ligands, as well as limitations of using cell extracts for the assessment of mechanisms of mRNA translation are discussed. Possible reasons for the discordant findings of Yan and colleagues and Westman and colleagues are suggested, and direct observation of the specific binding of ribavirin to eIF4E by using mass spectrometry is presented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16251386      PMCID: PMC1370864          DOI: 10.1261/rna.2238705

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  21 in total

1.  A solubility-enhancement tag (SET) for NMR studies of poorly behaving proteins.

Authors:  P Zhou; A A Lugovskoy; G Wagner
Journal:  J Biomol NMR       Date:  2001-05       Impact factor: 2.835

Review 2.  Pleiotropic mechanisms of ribavirin antiviral activities.

Authors:  Zhi Hong; Craig E Cameron
Journal:  Prog Drug Res       Date:  2002

3.  Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.

Authors:  Yifei Yan; Yuri Svitkin; Joseph M Lee; Martin Bisaillon; Jerry Pelletier
Journal:  RNA       Date:  2005-08       Impact factor: 4.942

4.  Poly(A)-binding protein interaction with elF4G stimulates picornavirus IRES-dependent translation.

Authors:  Y V Svitkin; H Imataka; K Khaleghpour; A Kahvejian; H D Liebig; N Sonenberg
Journal:  RNA       Date:  2001-12       Impact factor: 4.942

5.  The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.

Authors:  A Kentsis; E C Dwyer; J M Perez; M Sharma; A Chen; Z Q Pan; K L Borden
Journal:  J Mol Biol       Date:  2001-09-28       Impact factor: 5.469

6.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.

Authors:  N Cohen; M Sharma; A Kentsis; J M Perez; S Strudwick; K L Borden
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

7.  Picornavirus IRESes and the poly(A) tail jointly promote cap-independent translation in a mammalian cell-free system.

Authors:  G Bergamini; T Preiss; M W Hentze
Journal:  RNA       Date:  2000-12       Impact factor: 4.942

8.  Tethered-function analysis reveals that elF4E can recruit ribosomes independent of its binding to the cap structure.

Authors:  E De Gregorio; J Baron; T Preiss; M W Hentze
Journal:  RNA       Date:  2001-01       Impact factor: 4.942

9.  Cap-Poly(A) synergy in mammalian cell-free extracts. Investigation of the requirements for poly(A)-mediated stimulation of translation initiation.

Authors:  Y M Michel; D Poncet; M Piron; K M Kean; A M Borman
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

10.  Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins.

Authors:  Anna Niedzwiecka; Joseph Marcotrigiano; Janusz Stepinski; Marzena Jankowska-Anyszka; Aleksandra Wyslouch-Cieszynska; Michal Dadlez; Anne-Claude Gingras; Pawel Mak; Edward Darzynkiewicz; Nahum Sonenberg; Stephen K Burley; Ryszard Stolarski
Journal:  J Mol Biol       Date:  2002-06-07       Impact factor: 5.469

View more
  37 in total

1.  Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.

Authors:  J Cao; X Sun; X Zhang; D Chen
Journal:  Clin Transl Oncol       Date:  2017-10-30       Impact factor: 3.405

2.  A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Authors:  Sarit Assouline; Biljana Culjkovic-Kraljacic; Julie Bergeron; Stephen Caplan; Eftihia Cocolakis; Caroline Lambert; Cara J Lau; Hiba Ahmad Zahreddine; Wilson H Miller; Katherine L B Borden
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

Review 3.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

Review 4.  Aiding and abetting cancer: mRNA export and the nuclear pore.

Authors:  Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Trends Cell Biol       Date:  2013-04-10       Impact factor: 20.808

5.  Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.

Authors:  Laurent Volpon; Michael J Osborne; Hiba Zahreddine; Andrea A Romeo; Katherine L B Borden
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

6.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

7.  The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.

Authors:  Biljana Culjkovic-Kraljacic; Aurélie Baguet; Laurent Volpon; Abdellatif Amri; Katherine L B Borden
Journal:  Cell Rep       Date:  2012-08-16       Impact factor: 9.423

Review 8.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

9.  Ribavirin targets eIF4E dependent Akt survival signaling.

Authors:  Keith Tan; Biljana Culjkovic; Abdellatif Amri; Katherine L B Borden
Journal:  Biochem Biophys Res Commun       Date:  2008-08-14       Impact factor: 3.575

10.  Targeting of protein translation as a new treatment paradigm for prostate cancer.

Authors:  Vidya P Ramamurthy; Senthilmurugan Ramalingam; Andrew K Kwegyir-Afful; Arif Hussain; Vincent C O Njar
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.